Cancer immunoediting is a process by which immune cells, particularly lymphocytes of the adaptive immune system, protect the host from the development of cancer and alter tumour progression by driving the outgrowth of tumour cells with decreased sensitivity to immune attack 1,2 . Carcinogen-induced mouse models of cancer have shown that primary tumour susceptibility is thereby enhanced in immune-compromised mice, whereas the capacity for such tumours to grow after transplantation into wild-type mice is reduced 2, 3 . However, many questions about the process of cancer immunoediting remain unanswered, in part because of the known antigenic complexity and heterogeneity of carcinogen-induced tumours 4 . Here we adapted a genetically engineered, autochthonous mouse model of sarcomagenesis to investigate the process of cancer immunoediting. This system allows us to monitor the onset and growth of immunogenic and non-immunogenic tumours induced in situ that harbour identical genetic and histopathological characteristics. By comparing the development of such tumours in immune-competent mice with their development in mice with broad immunodeficiency or specific antigenic tolerance, we show that recognition of tumour-specific antigens by lymphocytes is critical for immunoediting against sarcomas. Furthermore, primary sarcomas were edited to become less immunogenic through the selective outgrowth of cells that were able to escape T lymphocyte attack. Loss of tumour antigen expression or presentation on major histocompatibility complex I was necessary and sufficient for this immunoediting process to occur. These results highlight the importance of tumour-specific-antigen expression in immune surveillance, and potentially, immunotherapy.
To determine whether T lymphocytes influence tumour development, we adapted a mouse model of human soft tissue sarcomagenesis driven by Cre/LoxP-regulated expression of oncogenic K-ras G12D and deletion of p53 to allow for the control of tumour immunogenicity 5 . Sarcomas were induced in either immunecompetent Kras LSL-G12D/1 ;p53 fl/fl ;Rag2 1/2 (KP) or lymphocytedeficient Kras LSL-G12D/1 ;p53 fl/fl ;Rag2 2/2 (KPR) mice by intramuscular injection of lentiviral vectors that expressed Cre recombinase alone (Lenti-x). To induce sarcomas with potentially immunogenic antigens, we used vectors that also expressed the T-cell antigens SIYRYYGL (SIY) and two antigens from ovalbumin (SIINFEKL (SIN, OVA 257-264 ) and OVA 323-339 ) fused to the carboxy terminus of luciferase (Lenti-LucOS). Intramuscular injection of Lenti-LucOS led to tumour formation in 100% of KPR mice but only 27% of KP mice by 140 days ( Fig. 1a , P , 0.0001). Additional sarcomas ultimately developed in KP mice but with dramatically delayed kinetics (latency of 194.8 6 43.4 days) compared with KPR mice (73.6 6 4.3 days) ( Fig. 1c , P , 0.02). We also observed a difference in the penetrance of sarcoma development in KPR versus KP mice by 140 days with Lenti-x (89% versus 43%, respectively), although the difference was less dramatic than observed with Lenti-LucOS ( Fig. 1b , P , 0.0005). This suggests that in this model, tumour immunosurveillance may not necessitate the introduction of highly immunogenic tumour-specific antigens (TSAs). The observed immunosurveillance against Lenti-x tumours could result from the lentiviral infection required to induce tumours, the acquisition of TSAs during tumour development, or the immunogenicity of Cre itself. However, in a previous study, we found that Cre was not highly immunogenic when expressed in developing lung adenocarcinomas 6 . Although Lenti-x-induced sarcoma development was slightly delayed in immune-competent (KP) mice (114.9 days in KP versus 79.5 days in KPR mice), it was not significant ( Fig. 1c , P 5 0.11). The increased latency that is specific to Lenti-LucOS tumours may be the result of an equilibrium between replicating tumour cells and T cells that recognize antigens expressed from the LucOS vector and restrain tumour progression 1,7 .
Rag2 (recombination activating gene 2) deficiency prevents both T and B lymphocyte development and, therefore, could have pleiotropic effects on the immune response to tumour antigens. the significance of T-cell responses, we treated mice with antibodies against CD4 and CD8 to deplete T cells concurrent with, or subsequent to, intramuscular injection of Lenti-LucOS. T-cell depletion at tumour initiation, or even 14 days after tumour initiation, led to sarcoma development with complete penetrance and early onset similar to KPR mice ( Fig. 1d , P 5 0.001 and P 5 0.013 compared to untreated, respectively). To specifically test the importance of CD8 1 T cells that recognize the model TSAs, we made use of a regulatable luciferase-SIY fusion gene engineered into the murine Rosa26 locus (R26 LSL-LSIY ) 8 . These mice develop specific tolerance to luciferase and SIY due to weak thymic expression and deletion of reactive T cells ( Supplementary Fig. 1) 8 . Kras LSL-G12D/1 ;p53 fl/fl ;R26 LSL-LSIY/1 (KP-LSIY) mice injected with Lenti-LucS, a lenti-vector that expresses Cre and SIY fused to luciferase, were more susceptible to sarcoma formation and developed tumours earlier than KP littermates ( Fig. 1e , P 5 0.058). Thus, lymphocyte-mediated protection from sarcoma formation requires CD8 1 T cells that respond to non-self antigens expressed in tumours.
A key advantage of this conditional, genetically engineered cancer model over carcinogen-induced models is the capacity to track endogenous T cells specific for tumour antigens during primary tumour development. We used SIY and SIN loaded MHCI/K b reagents to track tumour-reactive CD8 1 T cells by flow cytometry. Only mice with Lenti-LucOS sarcomas harboured CD8 1 T cells specific to SIY and SIN in the lymph nodes nearest the tumour site as well as in the spleen ( Fig. 2a, b ). These CD8 1 T cells appeared to be completely functional because they produced both IFN-c and TNF-a upon stimulation ( Fig. 2a-d ). Interestingly, this contrasts sharply with results from an analogous model of lung adenocarcinoma in which the activity of T cells responding to the same tumour antigens was very weak, suggesting that different tumour types may use different mechanisms to escape immune attack 6 . We also investigated whether KP mice that did not develop sarcomas after injection with Lenti-LucOS harboured antigen-specific T cells, because such T cells could have protected these mice from sarcoma development. Indeed, we detected fully functional antigen-specific T cells in these mice (Fig. 2c, d and Supplementary  Fig. 1) , demonstrating that T cells specific to these model TSAs are functional and probably provide significant protection against the development of Lenti-LucOS sarcomas.
Pivotal experiments using methylcholanthrene (MCA)-induced sarcomas revealed that tumours generated in immune-compromised mice, and thus not immunoedited, are more susceptible to rejection upon transplantation into immune-competent mice 2 . To assay whether autochthonous sarcomas driven by targeted genetic mutations would also display an unedited phenotype, we transplanted independently derived sarcomas from KPR or KP mice into either wild-type or Rag2 2/2 mice. Whereas freshly isolated Lenti-LucOS-induced tumours (or cell lines) generated in KP mice grew similarly upon transplantation into either wild-type or Rag2 2/2 mice, most Lenti-LucOS tumours generated in KPR mice were rejected (1/7) or had significantly delayed growth (4/7) ( Fig. 3a, b and Supplementary Fig. 2 ). These results recapitulate the original findings from carcinogen-induced sarcomas in a genetically engineered mouse model of sarcomagenesis. 
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Next we wanted to determine whether Lenti-x-induced sarcomas, which lack the strong T-cell antigens from LucOS, would yield similar results. Interestingly, Lenti-x tumours generated in KPR or KP mice grew equally well when transplanted into wild-type or Rag2 2/2 mice (Fig. 3c, d) . It is noteworthy that while autochthonous tumours initiated by Lenti-x appeared partially inhibited by an adaptive immune response ( Fig. 1b) , in the context of transplantation, we found no evidence of immunoediting (Fig. 3c) . This difference may be due to Rag-dependent innate immune cells (NKT and cd T cells) that recognize stress or inflammatory ligands. These cells may be sufficient to eliminate a limited number of nascent tumour cells in the context of transformation by lentiviral infection, but not in response to the transplantation of fully developed tumours 1,9 . Nevertheless, we suggest that Lenti-x sarcomas from KPR mice grew unabated after transplantation into KP mice because immunoediting by T lymphocytes requires potent TSAs, which these tumours lack. The observed immunogenicity of carcinogen-induced sarcomas generated in immune-compromised mice may be due to the de novo generation of potent tumour neoantigens during transformation with mutagens [9] [10] [11] [12] . Importantly, in another study reported in this issue 13 , somatically mutated spectrin-b2 in a MCA-induced sarcoma was found to act as a potent neoantigen that drove the immunoediting process. In an attempt to introduce immunogenic mutations in Lenti-x tumours, we treated cell lines from these tumours with MCA in vitro. Interestingly, such treatment rarely yielded clones with increased immunogenicity (Supplementary Fig. 3 ). This may indicate that although carcinogens can produce mutations that are immunogenic, it may be a rare event.
If cancer immunoediting by lymphocytes requires potent TSAs, then Lenti-LucOS-induced tumours that appear edited after forming in KP mice may have evaded an immune response by the selective outgrowth of cells lacking these potent antigens [14] [15] [16] . To assess antigen expression, we measured luciferase activity in tumours. Whereas tumours from KPR mice were universally luciferase positive, tumours from KP mice had drastically reduced luciferase activity in all but one of six sarcomas (Fig. 4a, b) . Interestingly, this sarcoma had significantly reduced expression of H-2K b , the MHC class I allele responsible for presenting the SIY and SIN antigens (Fig. 4c ). Sarcomas from KP mice treated with anti-CD4 and anti-CD8 antibodies at tumour initiation also retained luciferase activity (5/6 sarcomas luc 1 , Fig. 4a ). However, fewer sarcomas retained luciferase expression when mice were treated with anti-CD4 and anti-CD8 antibodies beginning 14 days after tumour initiation (1/5 sarcomas luc 1 ), suggesting that immunoediting can occur very early during sarcoma development. Thus, by selectively eliminating cells that express potent TSAs, T lymphocytes drive the escape of tumour cells that either do not express potent antigens or cannot present the antigens to reactive T cells.
In a similar fashion to the antigen loss observed in autochthonous sarcomas, Lenti-LucOS-induced sarcomas from KPR mice lost antigen expression when transplanted into wild-type mice ( Supplementary  Fig. 4 ). Importantly, tumours that lost antigen expression after being passaged through wild-type mice grew comparably upon secondary transplantation into wild-type and Rag2 2/2 mice, whereas tumours passaged through Rag2 2/2 mice did not ( Supplementary Fig. 4 ). To test whether antigen loss was sufficient to provide a means of escape for Lenti-LucOS sarcomas generated in KP mice, we reintroduced the LucOS antigens into sarcomas that had lost expression of the antigens after passage through wild-type mice (referred to as antigen 2 tumours). Indeed, re-expression of LucOS led to severely reduced tumour growth (Fig. 4d) , indicating that loss of antigen expression was the primary means of tumour escape in this setting.
Epigenetic silencing of tumour antigen expression via DNA methylation could be responsible for antigen loss and tumour escape 17, 18 . To test this hypothesis, we treated cell lines that had lost luciferase expression after transplantation into immune-competent mice with 5-aza-29-deoxycytidine (Aza), which reverses epigenetic silencing by inhibiting DNA methylation. In several lines tested, luciferase activity was restored with Aza treatment (Fig. 4e) . Therefore, epigenetic silencing of tumour antigens may represent an important mechanism by which tumours can be edited in response to immune surveillance.
Here we have overcome many of the obstacles of carcinogeninduced models of cancer by using an autochthonous, genetically engineered model of sarcomagenesis to show that T lymphocytedriven tumour antigen loss is a critical means by which cancer immunoediting occurs in a primary tumour setting. Although this study was limited to investigating the role of anti-tumour immunity by T cells, this model could be adapted to investigate the role of other critical immune cells in cancer immunoediting, such as B cells or NK cells, by either introducing surface-expressed or stress-related antigens into Supplementary Fig. 2 for growth curves of tumour lines.
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tumours, respectively [19] [20] [21] . This study resulted in two key discoveries. First, oncogene-driven, endogenous tumours can undergo immunoediting in a manner similar to carcinogen-driven tumours if engineered to express model TSAs. The immunogenicity of MCA-induced sarcomas is well-documented, and may be a direct consequence of TSAs that arise from carcinogen-induced mutations of normal genes during tumour development 9, [11] [12] [13] . In contrast, cancers that arise spontaneously or by targeted genetic mutations in mice have been reported to be weakly immunogenic [22] [23] [24] [25] . However, the mutational requirements for tumorigenesis in humans may be greater than in mice 26 , and thus it is possible that spontaneous or genetically engineered mouse models of cancer might underestimate the mutational and antigenic load of most human cancers. This idea is supported by the second critical finding of this study-that tumour immunogenicity is not a universal characteristic of cancer development. By obviating the need for carcinogens, we could induce sarcomas that potentially lacked potent TSAs. These tumours had significantly reduced immunogenicity despite no previous engagement with the adaptive immune system and hence no opportunity for immunoediting. These results provide the first (to our knowledge) experimental system to unify the apparently conflicting results obtained using either carcinogen-induced or genetically targeted mouse models of cancer by identifying TSAs as the critical determinants that invoke adaptive immunosurveillance and immunoediting 2, 22 . We propose that identifying and characterizing TSAs in human cancers may be critical for the generation of more effective anti-cancer immunotherapies in patients suffering from this disease.
METHODS SUMMARY
Experiments used mice of the 129S 4 /SvJae strain. All animal studies and procedures were approved by the Massachusetts Institute of Technology's Committee for Animal Care. Sarcomas were induced in KP and KPR mice by intramuscular injection of the hind limb with replication-incompetent lentiviruses expressing Cre recombinase as reported previously 5, 6 . To deplete T cells, anti-CD4 (GK1.5) and anti-CD8 (YTS169.4) antibodies were administered at a dose of 250 mg per mouse by i.p. injection once weekly for the duration of the experiment. Flow cytometry was performed as described 6 . For transplantation experiments, 2 3 10 5 freshly isolated tumour cells or cultured tumour cells were transplanted subcutaneously into immune-competent or Rag2 
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